Spero Therapeutics Inc

2HA

Company Profile

  • Business description

    Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

  • Contact

    675 Massachusetts Avenue
    14th Floor
    CambridgeMA02139
    USA

    T: +1 857 242-1600

    E: [email protected]

    https://www.sperotherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    25

Stocks News & Analysis

stocks

Global tensions drive profitability for ASX energy provider

Supply disruptions turbocharge refining profits and lift earnings forecasts for ASX energy share.
stocks

ASX energy share undervalued ahead of earnings

Pricing strength outweighs temporary production headwinds.
stocks

Tesla: Reported China divestiture plan could clear path for SpaceX merger

Media report says Tesla is exploring divestiture plans to ease regulatory approval of a Tesla-SpaceX merger.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,311.90125.801.37%
CAC 408,666.6352.810.61%
DAX 4026,223.26221.950.85%
Dow JONES (US)54,044.52866.111.63%
FTSE 10010,879.3821.680.20%
HKSE25,852.92156.48-0.60%
NASDAQ26,423.17509.271.97%
Nikkei 22563,957.53202.630.32%
NZX 50 Index13,903.46128.530.93%
S&P 5007,706.94106.441.40%
S&P/ASX 2009,145.80122.801.36%
SSE Composite Index3,822.2812.620.33%

Market Movers